Quick Answer
Zymeworks Inc. reported Operating Income Loss of -$92.55 million for the year ending 2025.
- Zymeworks Inc. showed an increase of +32.5% in Operating Income Loss from 2024 to 2025.
- This data is from Zymeworks Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: -$60.96 million | Q1 2022: -$72.69 million | Q2 2022: -$65.82 million | Q3 2022: -$50.36 million | Q1 2023: -$27.28 million | Q2 2023: -$54.11 million | Q3 2023: -$33.24 million | Q1 2024: -$37.80 million | Q2 2024: -$42.89 million | Q3 2024: -$34.21 million | Q1 2025: -$25.61 million | Q2 2025: -$674.0 thousand | Q3 2025: -$22.11 million.
- Over the full 6 years of available data (2020 to 2025), Zymeworks Inc.'s Operating Income Loss has grown by 50.6%.
- Historical annual values: Fiscal year 2025: -$92.55 million | Fiscal year 2024: -$137.11 million | Fiscal year 2023: -$138.05 million | Fiscal year 2022: $130.53 million | Fiscal year 2021: -$215.63 million | Fiscal year 2020: -$187.47 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: